MILAN, Italy, July 23 /PRNewswire-FirstCall/ -- Eurand N.V. will host a conference call on Friday, August 3, 2007 at 8:30 a.m. Eastern Daylight Time, 2:30 p.m. Central Europe Summer Time covering first half 2007 financial results. Earnings will be announced on the same day before the market opens in the United States.
The conference call to review the results will be hosted by Gearóid Faherty, Chief Executive Officer, and Mario Crovetto, Chief Financial Officer.
Conference call schedule: 8:00 am EDT: First Half 2007 results will be distributed 8:20 am EDT: To participate in the conference call, -- US Participants dial 1 888 935 4575 -- International Participants dial +1 718 354 1387 8:30 am EDT: Conference call begins promptly Call Replay: A replay of the call will be available until August 10, 2007. The passcode to access the replay is 1123416# -- US Participants dial 1 888 883 4489 -- International Participants dial +1 718 354 1112
Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to investors, members of the news media and the general public. This event can be accessed by visiting Eurand’s website at http://www.eurand.com. Following the live webcast, an archived version of the call will be available at the same URL.
About Eurand
Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2000 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand has completed two phase III clinical trials on its lead product candidate Zentase(TM) for the treatment of Exocrine Pancreatic Insufficiency and filed an NDA for this product in June 2007. Eurand’s technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-making/fast-dissolving formulations and drug conjugation.
Eurand is a global company with facilities in the USA and Europe. For more information, visit Eurand’s website at http://www.eurand.com.
This release, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to our plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words “potentially”, “could”, “calls for” and similar expressions also identify forward-looking statements. These statements are based upon management’s current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA refuses to approve our NDA; the outcome of any discussions with the FDA; and unexpected delays in preparation of materials for submission to the FDA as a part of our NDA filing. Forward- looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward- looking statements.
Eurand
CONTACT: Marian Cutler of Eurand, +1-973-517-0519
Web site: http://www.eurand.com//
